stockrow
Friday 6 November 2026
Export BLRX’s income statement to Excel — free account
BioLineRx Ltd.
BLRX Healthcare Biotechnology
BioLineRx Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $1.2 million, down 95.9% from fiscal 2024.
- Revenue
- −3.29%
- EPS
- +31.9%
- Free cash flow
- −1,827.7%
- Total debt
- −40.2%
Quarter to June 2026, against a year earlier
1.77
0.09
−4.84%
Follow BLRX
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | 5 | 29 | 1 | 1 | (50.4%) | 2 | 2 | 8 | +88.0% | |
| Gross margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 23.08 | 67.99 | 80.51 | 80.03 | +80.5 pt | ||||||
| EBT | (16) | (24) | (23) | (25) | (30) | (27) | (25) | (61) | (9) | (2) | (10) | (20.4%) | ||||||
| EBT margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (1,262.79) | (31.86) | (171.69) | (728.45) | (171.7) pt | ||||||
| Net income | (16) | (24) | (23) | (25) | (30) | (27) | (25) | (61) | (9) | (2) | (10) | (20.4%) | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.99 | 14.49 | 0.29 | 0.31 | n/m | |||||
| Earnings | (167.92) | (161.92) | (125.94) | (102.00) | (72.00) | (24.00) | (19.20) | (37.60) | (4.62) | (0.29) | (1.60) | (50.7%) | ||||||
| Cash flow | (155.05) | (136.98) | (133.66) | (92.89) | (55.07) | (21.33) | (20.34) | (14.08) | (21.97) | (1.96) | (2.43) | (38.5%) | ||||||
| Capex | (0.59) | (28.25) | (56.44) | (0.30) | 0.00 | (0.09) | (0.24) | (0.18) | (0.03) | (0.01) | 0.00 | (39.3%) | ||||||
| Free cash flow | (155.64) | (165.23) | (190.10) | (93.19) | (55.07) | (21.42) | (20.59) | (14.27) | (22.00) | (1.97) | (2.43) | (38.5%) | ||||||
| Book value | 374.22 | 352.54 | 228.29 | 136.80 | 52.28 | 61.62 | 39.41 | 8.24 | 6.74 | 5.68 | 3.74 | (37.2%) | ||||||
| Shares, m | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 2 | 2 | 4 | 4 | +52.2% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 | |||||
| P/S | — | — | — | — | — | — | — | 0.00 | 0.59 | 9.65 | 5.65 | 3.4 | ||||||
| P/B | — | — | — | — | — | — | — | 8.32 | 1.27 | 0.49 | 0.47 | 3.4 | ||||||
| EV/Sales | — | — | — | — | — | — | — | 0.00 | 0.38 | (0.47) | 1.06 | 0.0 | ||||||
| EV/FCF | — | — | — | — | — | — | — | (3.35) | (0.25) | 0.07 | (0.14) | (1.2) | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | (15) | (21) | (24) | (23) | (23) | (24) | (26) | (23) | (44) | (8) | (11) | (6.3%) | |||||
| Capex | 0 | (4) | (10) | 0 | — | 0 | 0 | 0 | 0 | 0 | 0 | (7.6%) | ||||||
| Free cash flow | (15) | (25) | (34) | (23) | (23) | (24) | (27) | (23) | (44) | (8) | (11) | (6.3%) | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | 32 | 44 | 25 | 16 | 12 | 48 | 41 | 4 | 12 | 12 | 3 | (10.8%) | |||||
| Net debt | (35) | (49) | (21) | (19) | (17) | (53) | (41) | (33) | (6) | (12) | (6) | (11.3%) | ||||||
| Shareholders’ equity | 35 | 53 | 41 | 33 | 22 | 68 | 51 | 13 | 13 | 23 | 17 | (4.4%) | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | (35.11) | (48.75) | (39.18) | (46.35) | (59.53) | (42.05) | (31.63) | (86.40) | (17.93) | (2.94) | (18.21) | +32.2 pt | |||||
| ROIC | 0.00 | (432.43) | (80.41) | (122.16) | (271.65) | (100.28) | (183.57) | 0.00 | (173.87) | (56.36) | (74.28) | (56.4) pt | ||||||
| ROE | (38.34) | (55.40) | (48.75) | (68.13) | (108.36) | (60.04) | (41.96) | (189.23) | (69.11) | (6.38) | (38.10) | +32.0 pt | ||||||
| People | ||||||||||||||||||
| People | Employees | 43 | 51 | 48 | 42 | 38 | 38 | 49 | 79 | 28 | 24 | — | (6.3%) | |||||
| Revenue/emp, $m | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.06 | 1.03 | 0.05 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2025 · latest quarter Jun 2026 · fundamentals updated 26 Oct 2026
BioLineRx Ltd. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| ACTU Actuate Therapeutics, Inc. | $18.0M | — (loss-making) | — | — | n/m | −5.54% (below 0%: shrinking) | — | 0.00% | Compare |
| ICU SeaStar Medical Holding Corporation | $10.2M | — (loss-making) | — (loss-making) | +81.95% (above 0%: growing) | n/m | +0.43% (above 0%: growing) | 91.22% | (616.42%) | Compare |
| MBRX Moleculin Biotech, Inc. | $9.2M | 0.0× | — | — | n/m | −19.26% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| CURX Curanex Pharmaceuticals Inc | $9.1M | — (loss-making) | — | — | n/m | −272.32% (below 0%: shrinking) | — | 0.00% | Compare |
| CMMB Chemomab Therapeutics Ltd. Sponsored ADR | $9.1M | — (loss-making) | — | — | n/m | +47.89% (above 0%: growing) | 0.00% | 0.00% | Compare |
| CALC CalciMedica Inc. | $8.9M | — (loss-making) | — | — | n/m | +31.42% (above 0%: growing) | 0.00% | 0.00% | Compare |
| BLRX BioLineRx Ltd. | $8.8M | — (loss-making) | — (loss-making) | −3.29% (below 0%: shrinking) | n/m | −1,827.71% (below 0%: shrinking) | 79.93% | (1,215.31%) | |
| INAB IN8bio, Inc. | $8.2M | — (loss-making) | — | — | n/m | −1.30% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| TPST Tempest Therapeutics, Inc. | $7.5M | — (loss-making) | — | −71.57% (below 0%: shrinking) | n/m | +67.04% (above 0%: growing) | 0.00% | 0.00% | Compare |
| Median of peers | $9.1M | — | — | — | — | −0.43% | 0.00% | 0.00% |